Anti-lysobisphosphatidic acid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus
Open Access
- 7 February 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 140 (1) , 173-180
Abstract
Lyso(bis)phosphatidic acid (LBPA) is a novel antigenic target in anti‐phospholipid syndrome (APS) and antibodies directed against LBPA (aLBPA) have been detected in sera from APS patients. In this study we first evaluated aLBPA in comparison with the most widely used methods (i.e. anticardiolipin [(aCL)‐enzyme‐linked immunosorbent assay (ELISA)] and antibeta‐2‐glycoprotein‐I antibodies (aβ2‐GPI‐ELISA) utilized to detect antiphospholipid antibodies in patients with primary or secondary APS, systemic lupus erythematosus, chronic HCV infection and healthy subjects. We then assessed the relationship between aLBPA, lupus anticoagulant (LAC) and the main clinical manifestations of APS. Finally, we evaluated the presence of ‘pure’ (i.e. β2‐GPI‐independent) aLBPA in patients with APS and controls. The results indicate that aLBPA as well as aβ2‐GPI display higher specificity but lower sensitivity for APS compared to aCL. Moreover, serum aLBPA correlate closely with aCL and aβ2‐GPI in APS patients and are strictly associated with LAC positivity. We demonstrate that β2‐GPI binds to LBPA with affinity similar to CL, and antibodies able to react with phosholipid‐protein complex exist; however, ‘pure’ aLBPA can also be detected in sera of APS patients. Altogether these data confirm that LBPA may be an antigenic target in APS and that aLBPA are serological markers of APS with similar sensitivity and specificity compared to aβ2‐GPI. However, the clinical utility of aLBPA detection alone or in combination with aCL and/or aβ2‐GPI remains to be elucidated in larger and longitudinal studies.Keywords
This publication has 41 references indexed in Scilit:
- Cardiolipin and its metabolites move from mitochondria to other cellular membranes during death receptor-mediated apoptosisCell Death & Differentiation, 2004
- Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodiesClinical Immunology, 2004
- Interaction of Anti-Phospholipid Antibodies With Late Endosomes of Human Endothelial CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- Characterization of IgG monoclonal anti‐cardiolipin/anti‐β2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodiesBritish Journal of Haematology, 1999
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—A meta-analysisLupus, 1997
- Anticardiolipin antibodies in chronic hepatitis C: Implication of hepatitis C virus as the cause of the antiphospholipid syndromHepatology, 1996
- Membranes and sortingCurrent Opinion in Cell Biology, 1995
- Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactorThe Lancet, 1990